Rapid Micro Biosystems reports Q4 EPS (28c), consensus (23c)

Reports Q4 revenue $11.3M, consensus $10.93M. “We closed 2025 with significant momentum, delivering 20% year-over-year revenue growth,” said Robert Spignesi, President and CEO. “Our performance was highlighted by key commercial wins, including a record multi-system order from Amgen in the fourth quarter. This trajectory has continued into 2026, underscored by a meaningful multi-system order from Samsung Biologics in the first quarter. These milestones demonstrate the accelerating global adoption of the Growth Direct platform as our customers standardize on our technology across their manufacturing networks. Looking ahead, we expect our proven track record of consistent execution to further advance our strategic priorities of accelerating Growth Direct system placements, expanding gross margin, delivering new product innovation and prudently managing our cash.”